Crispr Therapeutics AG (CRSP)
CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310
CRISPR Therapeutics (CRSP) remains a "Strong Buy," supported by robust CASGEVY sales growth and pipeline expansion. CASGEVY achieved $76 million Q2 2026 sales, up 151% YoY, and now targets SCD and TDT patients as young as 2 years old. CTX310 demonstrated promising phase 1 results in lipid disorders, with key data updates expected at ESC Congress and in H2 2026.
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $1.29 per share a year ago.
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $48.44, moving +1.68% from the previous trading session.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $46.54, indicating a -2.08% shift from the previous trading day.
Crispr Therapeutics: A Catalyst-Rich 12 Months Ahead
CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead approved asset and multiple upcoming catalysts. CRSP's valuation reflects a 38% drawdown from its 52-week high, while several clinical data readouts and trial initiations are imminent. CASGEVY's efficacy and expanding market access, combined with a robust cash position, underpin a favorable risk/reward at current levels.
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $47.78, marking a -1.63% move from the previous day.
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
CRISPR Therapeutics AG (CRSP) reached $48.57 at the closing of the latest trading day, reflecting a -5.45% change compared to its last close.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
